10 Pharma

10 Pharma is a Japanese biotechnology company specializing in drug repositioning to address unmet medical needs in rare and intractable diseases. The company utilizes a proprietary screening platform to identify new therapeutic applications for existing, clinically-validated compounds, thereby reducing development risks and timelines. Its lead candidate, 10P-001, is currently in Phase 2 clinical trials for the treatment of Duchenne Muscular Dystrophy (DMD). 10 Pharma's pipeline also includes programs targeting Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative conditions. By leveraging established safety profiles of known drugs, the company aims to accelerate the delivery of life-changing therapies to patients.